← All Signals

🏥 FDA: K.C. Pharmaceuticals, Inc — Class II

healthcareactionableSource: FDA
95%Confidence
0Views
FDASource
2026-04-15Date

Summary

K.C. Pharmaceuticals' sterility assurance failure for multiple eye drop products distributed through major retailers creates significant public health risks. This affects Cardinal Health, Perrigo, and other distributors who may face product recalls and reputational damage.

Actionable: Immediately review inventory of affected eye drop products and prepare for potential consumer advisories.

AI Confidence: 95%

Data Points

firmK.C. Pharmaceuticals, Inc
classificationClass II
statusOngoing
distributionNationwide in the US
productArtificial Tears Sterile Lubricant Eye Drops (polyvinyl alcohol 0.5%, povidone 0.6%), 0.5 FL OZ (15 mL) bottles; a) LEADER, DISTRIBUTED BY CARDINAL HE

Get Signals Instantly

Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.

Subscribe Now